Using Cenobamate for managing idiopathic generalized epilepsy: A single‐center experience and systematic literature review

Cenobamate (CNB), an anti-seizure medicine, was studied for off-label use in 16 adults with drug-resistant idiopathic generalized epilepsy (IGE). Most had juvenile myoclonic epilepsy and long-standing seizures despite many prior treatments. Over half continued CNB for at least 12 months, and around 30% stopped within 3 months. At 3, 6, and 12 months, 63%-86% had at least 50% fewer seizures; three patients became seizure-free. Emergency visits dropped significantly after starting CNB. Common side effects were fatigue, dizziness, and cognitive issues. These findings suggest CNB can help reduce seizures and healthcare use in adults with difficult-to-treat IGE, warranting further study.